-
公开(公告)号：EP0867190B1
公开(公告)日：2007-12-26
申请号：EP96913722.3
申请日：1996-05-10
发明人： SUZAWA, Toshiyuki , YAMASAKI, Motoo , NAGAMURA, Satoru , SAITO, Hiromitsu , OHTA, So , HANAI, Nobuo
IPC分类号： A61K47/48
CPC分类号： A61K39/44 , A61K47/6809 , A61K47/6817 , A61K47/6889 , C07K17/06
摘要： A toxin complex prepared by bonding a residue of a compound having target cell affinity and a residue of toxin via a spacer containing a polyalkylene glycol and a dipeptide.
摘要翻译： 通过含有聚亚烷基二醇和二肽的间隔物结合具有靶细胞亲和性的化合物的残基和毒素的残基而制备的毒素复合物。
-
公开(公告)号：EP0760376A1
公开(公告)日：1997-03-05
申请号：EP96905021.0
申请日：1996-03-07
CPC分类号： C07K7/06 , A61K38/00 , C07K7/08 , C12N9/20 , Y02A50/475
摘要： Peptides inhibiting phospholiphase C which are represented by general formula (I), wherein n represents 0 or 1; J 1 and J 2 represent each hydrogen or form together a single bond; W represents hydrogen, optionally substituted alkanoyl, optionally substituted aroyl or coumaryl; X represents a single bond, -Leu- or -Ser-Leu-Val-Glu-Leu-Val-Ser-Tyr-Tyr-Glu-Lys-His-Ala-Leu optionally having the deletion, insertion or replacement of at least one amino acid residue; Y represents a single bond or -Pro-Val-; R 1 represents hydrogen, optionally substituted alkyl or optionally substituted aryl; and R 2 represents optionally substituted alkyl or optionally substituted aryl.
-
3.发明公开
公开(公告)号：EP0989136A1
公开(公告)日：2000-03-29
申请号：EP98919612.6
申请日：1998-05-15
发明人： SHIBATA, Kenji , YAMASAKI, Motoo , YOSHIDA, Tetsuo , MIZUKAMI, Tamio , SHINKAI, Akeo , ANAZAWA, Hideharu
IPC分类号： C07K14/82
CPC分类号： C07K7/08 , A61K38/00 , C07K7/52 , C07K7/64 , C07K14/4746
摘要： Peptides having cyclic structures represented by the following general formula(I): R 1 (X 1 ) n1 (X 2 ) n2 (X 3 ) n3 (X 4 ) n4 (X 5 ) n5 (X 6 ) n6 (X 7 ) n7 (X 8 ) n8 (X 9 ) n9 (X 10 ) n10 (x 11 )n 11 (X 12 ) n12 (X 13 ) n13 (X 14 ) n14 (X 15 ) n15 (X 16 ) n16 (X 17 ) n17 R2 and exerting the effect of restoring a P53 protein activity on P53 protein mutants or pharmacologically acceptable salts thereof. In said formula (I) X i means an arbitrary member selected from among X 1 to X 17 while n i means an arbitrary member selected from among n 1 to n 17 (provided that i is an integer of from 1 to 17), then X i represents an amino acid residue or an organic acid residue; a functional group in a residue X p selected among X 1 to X 11 (provided that p is an integer of from 1 to 11) and a functional group X q selected from among X 8 to X 17 (provided that q is an integer of from 8 to 17 and larger than p) form a cyclic structure having a crosslinkage selected from among S-S, S-CH 2 -S, S-CH 2 -C 6 H 4 ,-CH 2 -S, S-CH 2 -CO, CO-NH, NH-CO, O-CO or CO-O; R 1 represents optionally substituted alkanoyl, etc.; and R 2 represents optionally substitued alkoxy, etc.
摘要翻译： [R <1）
） （X <8>） ） R2和施加P53蛋白突变体或其药理学上可接受的盐还原P53蛋白活性的效果。 在所述式（I）中X的装置从X <1>到X <17>而Ñ装置从N中<1>选择到n的任意构件（提供<17>中选择的任意构件做 i是从1到17的整数），则X的 darstellt在氨基酸残基或有机残基; 在残基X 的官能团中选择的X <1>至X <11>（提供确实p是从1到11的整数）和选自X <8>到所选择的官能团X
X <17>（提供确实q是8至17中的整数，大于p）形成具有从SS，S-CH2-S，S-CH2-C6H4，CH2-S中选择的交联的环状结构， S-CH2-CO，CO-NH，NH-CO，O-CO或CO-O; [R <1> darstellt OPTIONALLY substituiertem烷酰基等; 且R <2> darstellt任意取代的烷氧基等
-
公开(公告)号：EP0795562A1
公开(公告)日：1997-09-17
申请号：EP95936110.6
申请日：1995-11-07
IPC分类号： C07K14/575 , A61K38/22
CPC分类号： C07K14/605 , A61K38/00 , Y10S514/866
摘要： A peptide represented by the following formula (I) or a pharmacologically acceptable salt thereof:
H-His-Ser-Gln-Gly-Thr-Phe-Thr-Asn-Asp-Tyr-Ser-Lys-Tyr-Leu-Glu-Thr-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Ser-Lys-Arg-Ser-Gly-Gly-Pro-Thr-OH. It has cardiotonic and insulin release accelerator effects and is useful for preventing or treating heart diseases or diabetes.摘要翻译： 由下式（I）表示的肽或其药理学上可接受的盐：H-His-Ser-Gln-Gly-Thr-Phe-Thr-Asn-Asp-Tyr-Ser-Lys-Tyr-Leu-Glu-Thr -Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Ser-Lys-Arg-Ser-Gl y-Gly-Pro-Thr-OH。 它具有强心剂和胰岛素释放促进剂作用，可用于预防或治疗心脏病或糖尿病。
-
公开(公告)号：EP0679658A1
公开(公告)日：1995-11-02
申请号：EP95904339.9
申请日：1994-06-23
发明人： SHIBATA, Kenji , SUZAWA, Toshiyuki , YAMASAKI, Motoo , TANAKA, Takeo , TSUKUDA, Eiji , YAMADA, Koji , OHNO, Tetsuji
CPC分类号： C07K7/06 , A61K38/00 , C07K14/57536
摘要： An endothelin-antagonizing peptide compound represented by general formula (I) and a pharmacologically acceptable salt thereof: R¹-R²-R³-R⁴-R⁵-R⁶-R⁷-R⁸-R⁹-R¹⁰-R¹¹-R¹²-Phe-R¹⁴-R¹⁵-R¹⁶-R¹⁷-R¹⁸-Ile-R²⁰-Z wherein R¹ is X¹-Gly, X³(a), X²-SCH₂CO or hydrogen; R² is Asn, Asp, Phe, Tyr, Ser or a single bond; R³ is Trp, Ile, Pro, Ala or a single bond; R⁴ is His, Lys, Gly, Trp, Ala or a single bond; R⁵ is Gly, Thr, Trp, Val or a single bond; R⁶ is Gly, Thr, Asn, Tyr, Asp or a single bond; R⁷ is Ala, Ser, Asn, Asp, Tyr, Phe or a single bond; R⁸ is Pro, Ala, Arg or a single bond; R⁹ is (b), (c) or a single bond; R¹⁰ is Trp or Ala; R¹¹ is Val, Pro or a single bond; R¹² is Tyr or a single bond; R¹⁴ is Ala, MeAla, Ser or Cys; R¹⁵ is His or Trp; R¹⁶ is Leu or Nva; R¹⁷ is Asp, Thr, Asn, Ser, Gly or Glu; R¹⁸ is Ile, Leu, Cha, Abu, Thi, Met, Tyr, MeLeu, MeIle, Phg or Nle; R²⁰ is Trp, Phe or Tyr; and Z is hydroxy, lower alkoxy or amino.
摘要翻译： 由通式（I）表示的内皮素拮抗肽化合物及其药理学上可接受的盐：R 1 -R 2 -R 3 -R 4 -R 5 -R 6 - R 7 -R 8 -R 9 -R 1 -R 1 1 -R 1 -P-R 1 - 4 - R 1 -R 5 -R 6 -R 1 -R 7 -R 8 -Ile-R 2 -Z其中R 1是X X 3（a），X 2 -SCH 2 CO或氢; R 2是Asn，Asp，Phe，Tyr，Ser或单键; R 3是Trp，Ile，Pro，Ala或单键; R 4是His，Lys，Gly，Trp，Ala或单键; R 5是Gly，Thr，Trp，Val或单键; R 6是Gly，Thr，Asn，Tyr，Asp或单键; R 7是Ala，Ser，Asn，Asp，Tyr，Phe或单键; Pro，Ala，Arg或单键; R 9为（b），（c）或单键; R 1是Trp或Ala; R 1是Val，Pro或单键; R 1是Tyr或单键; R 1是Ala，MeAla，Ser或Cys; R 1 <5>是His或Trp; R 1是Leu或Nva; R 1是Asp，Thr，Asn，Ser，Gly或Glu; R 1是Ile，Leu，Cha，Abu，Thi，Met，Tyr，MeLeu，MeIle，Phg或Nle; R 2是Trp，Phe或Tyr; Z是羟基，低级烷氧基或氨基。
-
公开(公告)号：EP0744409B9
公开(公告)日：2009-08-19
申请号：EP95909967.2
申请日：1995-02-23
IPC分类号： C07K14/535 , A61K38/19
CPC分类号： C07K14/535 , A61K38/00
摘要： A human granulocyte-colony stimulating polypeptide wherein at least one amino, carboxy, mercapto or guanidino group has been chemically modified by a chemical modifier; a platelet growth accelerator containing the polypeptide; a method of treating thrombocytopenic patients by administering an efficacious dose of the polypeptide; the use of the polypeptide for producing a pharmacological composition efficacious in treating thrombocytopenic patients; and a composition for treating thrombocytopenic patients comprising an efficacious dose of the polypeptide in a pharmacologically acceptable dosage form together with a pharmacologically acceptable carrier.
-
公开(公告)号：EP0744409B1
公开(公告)日：2008-08-06
申请号：EP95909967.2
申请日：1995-02-23
IPC分类号： C07K14/535 , A61K38/19
CPC分类号： C07K14/535 , A61K38/00
摘要： A human granulocyte-colony stimulating polypeptide wherein at least one amino, carboxy, mercapto or guanidino group has been chemically modified by a chemical modifier; a platelet growth accelerator containing the polypeptide; a method of treating thrombocytopenic patients by administering an efficacious dose of the polypeptide; the use of the polypeptide for producing a pharmacological composition efficacious in treating thrombocytopenic patients; and a composition for treating thrombocytopenic patients comprising an efficacious dose of the polypeptide in a pharmacologically acceptable dosage form together with a pharmacologically acceptable carrier.
-
公开(公告)号：EP0963999A1
公开(公告)日：1999-12-15
申请号：EP97941259.0
申请日：1997-09-26
CPC分类号： C07K14/4705 , A61K38/00
摘要： Compounds represented by the general formula (I): R 1 -A-R 2 or pharmacologically acceptable salts thereof wherein R 1 represents (un)substituted alkanoyl, (un)substituted aroyl, (un)substituted heteroarylcarbonyl, (un)substituted alkoxycarbonyl, (un)substituted aryloxycarbonyl, (un)substituted heteroaryloxycarbonyl, or hydrogen; R 2 represents hydroxy, (un)substituted alkoxy or (un)substituted amino; and A represents a partial peptide sequence comprising at least 12 consecutive amino acid residues in the sequence of a dimer forming or DNA binding region of each member of E2F family.
摘要翻译： 由通式（I）表示的化合物：R 1 -AR 2或其药理学上可接受的盐，其中R 1表示（un）取代的烷酰基，（un）取代的芳酰基，（未）取代的杂芳基羰基，（un ）取代的烷氧基羰基，（取代的）取代的芳氧基羰基，（取代的）取代的杂芳氧基羰基或氢; R 2表示羟基，（未）取代的烷氧基或（取代的）取代的氨基; 并且A表示在E2F家族的每个成员的二聚体形成或DNA结合区的序列中包含至少12个连续的氨基酸残基的部分肽序列。
-
公开(公告)号：EP0584374B1
公开(公告)日：1997-09-24
申请号：EP93905633.9
申请日：1993-03-11
IPC分类号： C12N9/16
摘要： A mutant peptide which has an activity of inhibiting phospholipase C and which is deficient in a peptide, or at least one amino acid residue thereof, having an amino acid sequence represented by sequence no. 1, has the peptide to which at least one amino acid residue is added, and/or is substituted by other amino acid residues or modified amino acid residues.
-
公开(公告)号：EP0783003B1
公开(公告)日：2006-11-22
申请号：EP96912262.1
申请日：1996-04-26
发明人： YOKOI, Haruhiko , SHIOTSU, Yukimasa , KONISHI, Noboru , ANAZAWA, Hideharu , TAMAOKI, Tatsuya , YAMASAKI, Motoo , TERASAKI, Yoko , UCHIDA, Kazuhisa , YAMASHITA, Kinya
CPC分类号： C07K14/535 , A61K38/00 , C07K14/52 , C07K14/524 , C07K2319/00
摘要： A fused polypeptide composed of a polypeptide having the G-CSF activity with another polypeptide having the TPO activity; a DNA encoding this fused polypeptide; a fused polypeptide wherein a polypeptide having the G-CSF activity has been fused with another polypeptide having the TPO activity via a spacer peptide; a DNA encoding this fused polypeptide; a polypeptide wherein the above-mentioned fused polypeptide composed of the polypeptide having the G-CSF activity with the polypeptide having the TPO activity has been further chemically modified with a polyalkylene glycol derivative; and a remedy for anemia containing such a fused polypeptide as the active ingredient.
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.018 秒)
